Trial Data Provide Proof-of-concept for CRX-1008 as Leptomeningeal FAP Treatment
CRX-1008, an investigational therapy also known as SOM0226 or tolcapone, is safe and well-tolerated by patients as a treatment for familial amyloid polyneuropathy (FAP), and can stabilize the TTR protein in the brain, new clinical trial data show. The findings provide a proof-of-concept for CRX-1008 as a treatment…